Literature DB >> 16091753

The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene.

Marina Bousquet1, Cathy Quelen, Véronique De Mas, Eliane Duchayne, Blandine Roquefeuil, Georges Delsol, Guy Laurent, Nicole Dastugue, Pierre Brousset.   

Abstract

Several tyrosine kinase genes are involved in chromosomal translocations in chronic myeloproliferative disorders, but there are still uncharacterized translocations in some cases. We report two such cases corresponding to atypical chronic myeloid leukaemia with a t(8;9)(p22;p24) translocation. By fluorescence in situ hybridisation (FISH) on the corresponding metaphases with a bacterial artificial chromosome probe encompassing the janus kinase 2 (JAK2) gene at 9p24, we observed a split for both patients, suggesting that this gene was rearranged. The locus at 8p22 contains different candidate genes including the pericentriolar material 1 gene (PCM1), already implicated in reciprocal translocations. The rearrangement of the PCM1 gene was demonstrated by FISH, for both patients. By RT-PCR, we confirmed the fusion of 3' part of JAK2 with the 5' part of PCM1. Sequence analysis of the chimeric PCM1-JAK2 mRNA suggests that the putative protein displays the coiled-coil domains of PCM1 and the tyrosine kinase domain of JAK2. This new translocation identifies JAK2 as a possible therapeutic target for compounds with anti-tyrosine kinase activity. Oncogene (2005) 24, 7248-7252. doi:10.1038/sj.onc.1208850; published online 8 August 2005.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16091753     DOI: 10.1038/sj.onc.1208850

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  25 in total

1.  Alternative TEL-JAK2 fusions associated with T-cell acute lymphoblastic leukemia and atypical chronic myelogenous leukemia dissected in zebrafish.

Authors:  Sara M N Onnebo; Parisa Rasighaemi; Janani Kumar; Clifford Liongue; Alister C Ward
Journal:  Haematologica       Date:  2012-06-24       Impact factor: 9.941

2.  Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies.

Authors:  Shashidhar S Jatiani; Stacey J Baker; Lewis R Silverman; E Premkumar Reddy
Journal:  Genes Cancer       Date:  2010-10

Review 3.  The use of structural biology in Janus kinase targeted drug discovery.

Authors:  Nilda L Alicea-Velázquez; Titus J Boggon
Journal:  Curr Drug Targets       Date:  2011-04       Impact factor: 3.465

Review 4.  A structure-function perspective of Jak2 mutations and implications for alternate drug design strategies: the road not taken.

Authors:  K Gnanasambandan; P P Sayeski
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

5.  JAK2 tyrosine kinase phosphorylates and is negatively regulated by centrosomal protein Ninein.

Authors:  Jennifer Jay; Alan Hammer; Andrea Nestor-Kalinoski; Maria Diakonova
Journal:  Mol Cell Biol       Date:  2014-10-20       Impact factor: 4.272

Review 6.  Interleukin 7 and thymic stromal lymphopoietin: from immunity to leukemia.

Authors:  Noa Tal; Chen Shochat; Ifat Geron; Dani Bercovich; Shai Izraeli
Journal:  Cell Mol Life Sci       Date:  2013-04-27       Impact factor: 9.261

7.  Expression of TEL-JAK2 in primary human hematopoietic cells drives erythropoietin-independent erythropoiesis and induces myelofibrosis in vivo.

Authors:  J A Kennedy; F Barabé; B J Patterson; J Bayani; J A Squire; D L Barber; J E Dick
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-31       Impact factor: 11.205

Review 8.  Janus kinases in immune cell signaling.

Authors:  Kamran Ghoreschi; Arian Laurence; John J O'Shea
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

Review 9.  The molecular regulation of Janus kinase (JAK) activation.

Authors:  Jeffrey J Babon; Isabelle S Lucet; James M Murphy; Nicos A Nicola; Leila N Varghese
Journal:  Biochem J       Date:  2014-08-15       Impact factor: 3.857

10.  Evolutional change of karyotype with t(8;9)(p22;p24) and HLA-DR immunophenotype in relapsed acute myeloid leukemia.

Authors:  Kuan-Po Huang; Andrew J Chase; Nicholas C P Cross; Andrea Reiter; Tzu-Ying Li; Tso-Fu Wang; Sung-Chao Chu; Xuan-Yin Lu; Chi-Cheng Li; Ruey-Ho Kao
Journal:  Int J Hematol       Date:  2008-07-02       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.